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Introduction
By 2013, there was a 40% decline in new paediatric infec-
tions compared to 2009. Prevention of mother to child trans-
mission (PMTCT) of HIV continues to reduce the frequency
of HIV in infants through wider and earlier implementation
of antenatal combination antiretroviral therapy (ART). Post-
natally, breastfed infants are now protected from HIV infec-
tion through maternal ART and/or infant nevirapine (NVP)
[1]. The ultimate aim is the elimination of vertical transmis-
sion of HIV.
Should HIV infection occur in infants, the focus is on early
detection and treatment. The children with HIV early anti-
retroviral (CHER) trial established the benefit of initiating ART
at a median of seven weeks of age [2,3]. The narrative of the
Mississippi child focussed attention on very early diagnosis
and therapy. This infant, whose mother was diagnosed as
HIV-positive in labour, initiated ART 31 hours after delivery.
After ART discontinuation from 15 to 21 months of age due
to poor adherence, plasma HIV RNA remained undetectable
on standard assays until almost four years of age, with only
traces of HIV DNA being found using sophisticated assays
[4,5].
Optimization of antenatal and post-natal
maternal HIV diagnosis
The main driver of mother to child transmission is the mater-
nal viral load. Although in utero infection has been observed
from 12 weeks’ gestation [6], it is likely that the majority
occur in the last two months of pregnancy [7]. Therefore,
antenatal ART is most effective when commenced by week
20 of pregnancy [8]. Pregnancy is time-limited. Every week of
delayed diagnosis increases the risk of vertical transmission.
Using data from studies until 2010, Johnson and colleagues
calculated that seroconversion late in pregnancy or during
breastfeeding contributes 28% of vertical infections, which
could be reduced through testing at 32 weeks’ gestation, and
at the six-week post-natal visit [9]. Many of these recom-
mendations have now been incorporated in MTCT guidelines,
with additional testing in seronegative breastfeeding mothers
at three-monthly intervals thereafter recommended [10].
Testing of sexual partners of HIV uninfected pregnant and
breastfeeding women may further prevent new acquisition.
While the rapid antibody tests are effective, the window
period for developing sufficient antibodies for a positive test
is between two and eight weeks, with almost 100% being
positive after 12 weeks [11]. A new innovation is the point of
care virological test, which will substantially increase diag-
nosis of acute HIV [12]. Dried blood spots offer an appro-
priate alternative for more resource-constrained settings [13].
Expanded testing should be offered for women where sig-
nificant risk of acute HIV is identified, for example, those
presenting with acute seroconversion illness or in high pre-
valence settings (Table 1  see suggested approach to improv-
ing maternal diagnosis and ART success).
Infant post-exposure prophylaxis when there is a
high risk of vertical transmission
For new HIV diagnosis in late pregnancy or labour, there is
a possibility of reducing risk of vertical transmission through
enhanced post-exposure prophylaxis. A randomized study of
post-exposure prophylaxis for infants born to women from
high prevalence settings where HIV was diagnosed late in
pregnancy and who received no antenatal ARVs, has contri-
buted many insights. The main objective was to determine
the best post-exposure regimen for infants at extremely
high risk for vertical HIV infection. Two antiretrovirals (ARVs)
(zidovudine [ZDV] for six weeks plus three doses of NVP in
the first week or three ARVs (ZDV, lamivudine [LMV] and
nelfinavir) for two weeks performed equally well and were
superior to ZDV given for six weeks in formula-fed infants
[14]. Given the superior efficacy of three ARVS compared to
two ARVs for treatment, many would have hoped that the
three-drug regimen would be better. Reasons for equivalence
include inability to achieve therapeutic exposure for nelfinavir
in 46% of infants, although nearly all had trough levels
above 0.05 mg/ml, 10 times the upper limit of nelfinavir IC50
for wild type HIV [15]. Also, the standard duration of post-
exposure prevention is four weeks, rather than the two
weeks used in this study [16]. Post-exposure prophylaxis for
28 days rather than a shorter period is supported by rhesus
macaque studies after simian immunodeficiency virus infec-
tion [17,18]. A recent cohort analysis from Europe showed
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that a three-ARV regimen for 28 days in post-exposure pro-
phylaxis is being used more frequently in circumstances
where there is a high risk of vertical transmission [19]. This
strategy is being widely adopted subsequent to the report of
the Mississippi baby [4] and experience in Canada [20].
Early infant diagnosis of HIV
In the post-exposure prophylaxis study by Nielsen-Saines
et al., a polymerase chain reaction (PCR) test on the first day
of life showed in utero infection in 5.7% of infants, illustrating
the importance of an immediate PCR when the risk of
transmission is high. There is a growing concern that both the
accuracy of diagnostic testing and relying on a single test in
the presence of ARV exposure are insufficient, leading to a
false sense of security. In one report, a PCR at 46 weeks of
age in formula-fed infants missed 32% of infections found at
three months of age. Other studies have confirmed the
inaccuracy of a single PCR at 46 weeks of age [21,22]. Point
of care virological testing may be useful on the first day of life
particularly where there is a high transmission risk but is
not essential provided that at least two blood specimens
are drawn for PCR in the first few days of life and triple ARV
prophylaxis is initiated as soon as possible after birth. The
latter should then be continued if the infant is HIV-infected.
Also, for breastfed infants regular virological testing of the
infant is essential until the infant is fully weaned (see
Table 2).
Conclusions
PMTCT approaches in high prevalence settings require urgent
adaptation to improve early infant diagnosis for the preven-
tion and management of HIV.
Table 1. Urgent maternal interventions to further reduce HIV PMTCT
Phase HIV status Intervention Rationale Comments
Antenatal Unknown Encourage first clinic visit and
initial HIV testing in first trimester
ART most effective when commenced
by 20 weeks’ gestation
Initial antibody
test negative
Repeat HIV testing later in
pregnancy and at delivery.
If antibody negative, use point
of care virological assay
Intimate partner testing for HIV
uninfected woman
Seroconversion in pregnancy can be
detected and infants identified for triple
ARV post-exposure prophylaxis.
Stratification of tests allows rational
usage of antibody and virological testing
Preventing maternal seroconversion
Initiate ART rapidly.
Raltegravir can be
added to more rapidly
reduce viral load
HIV Check ART adherence through
standard viral load assays at 32
weeks’ gestation and ensure no
missed pharmacy visits
Standard viral load assay often easily
available in many settings.
Pharmacy visits easy to measure
Standard test can be
replaced by point of
care assay if standard
test logistically difficult
During Delivery HIV Point of care virological test if
assay at 32 weeks’ gestation
above detectable limits
Identifies infants for ART prophylaxis
and early diagnosis
Previously HIV
negative or
unknown
Point of care antibody test
antibody test first; if negative, use
point of care virological assay
As above
Table 2. Urgent measures to increase early diagnosis, prevention and treatment in HIV-exposed infants
Timing Intervention Comment
At birth Commence post-exposure prophylaxis
using three ARVs for 4 weeks
Begin as soon as possible and take precedence over timing of
diagnostic tests. Convert to continued ART for a positive early test
2 separate blood draws for diagnostic
PCR tests or point of care virology test
plus confirmatory PCR
Confirmation of HIV status essential
46 weeks Repeat diagnostic PCR
12 weeks Repeat diagnostic PCR if negative at
46 weeks
Delayed positive test possible
For continued breastfeeding Repeat diagnostic PCR every 3 months
Rapid antibody test or virological
point of care test can be instituted at
9 months of age
This should continue until 6 weeks after fully weaned.A positive
rapid antibody test at 9 months may reflect slow disappearance
of maternal antibody and requires a diagnostic PCR or point of
care virology test
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